Herantis Pharma has initiated a non-invasive CDNF development program to broaden the application of CDNF in Parkinson’s disease and potentially other neurodegenerative disorders. In conjunction, Herantis and the University of Helsinki have signed a licensing […]
Sorrento Therapeutics has acquired Kimberly-Clark’s Sofusa lymphatic delivery technology platform for targeted biopharmaceuticals, particularly, the immune checkpoint inhibitors like anti-PD-1, CTLA4, CD47 antibodies and other I-O antibodies. Pioneered by inventor Dr. Russell F. Ross and […]
AbbVie’s Ibrutinib failed to meet its objective in a phase 3 trial DBL3001 in untreated diffuse large B-cell lymphoma patients. IMBRUVICA is a first-in-class Bruton’s tyrosine kinase inhibitor jointly developed and commercialized by Pharmacyclics LLC, […]
The Pharmaceutical Quality Group (PQG) issued a monograph on Pharmaceutical Distribution in 1997 and initiated planning to revise this in line with the new EU GDP regulatory guideline (a final revised version was issued in […]
SMi are delighted to have interviewed our speaker Naj Sharif, Executive Director and Head, Global Alliances & External Research, Santen regarding his thoughts and experiences within the ophthalmology space. Naj Sharif, PhD, FARVO, FBPhS was […]